Novavax says its COVID-19 vaccine is 90% effective

Monday - 14/06/2021 09:22
Unlike the Pfizer vaccine, Novavax’s version does not need special refrigeration, making it easier to distribute.

Novavax, a Maryland-based biotech company, announced Monday that its COVID-19 vaccine is 90.4% effective at preventing people from getting sick and 100% effective at preventing moderate or severe disease, hopefully laying the groundwork for a fourth vaccine in the fight against the coronavirus.

Nearly 30,000 participants across 119 sites in the U.S. and Mexico took part in the Phase 3 study, which evaluated “efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.”

Of those who got the two-shot inoculation, only 77 people tested positive for COVID-19, and all cases were “mild.” No hospitalizations or deaths were reported.

Among high-risk populations — those over age 65, under age 65 with certain comorbidities or having life circumstances with frequent COVID-19 exposure — the Novavax vaccine was 91% effective, the company said.

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” Novavax President and CEO Stanley Erck said in a statement.

“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines.”

Read More (...)


 Keywords: COVID-19

Total notes of this article: 0 in 0 rating

  Reader Comments

Newer articles

Older articles

You might also be interested in:
​Why Texas shooter was bullied at school  ​

​Why Texas shooter was bullied at school ​

Ramos, 18, killed at least 19 children and two teachers during his twisted massacre at the Robb...

You did not use the site, Click here to remain logged. Timeout: 60 second